CCTG MAC29 is investigating whether treatment with immunotherapy versus observation in people with early-stage triple-negative breast cancer (TNBC) who had a good response after initial treatment with chemotherapy and immunotherapy is really necessary.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Melanoma Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Melanoma Disease Site Committee, the Melanoma Disease Site Executive Committee, and the CCTG Patient Representative Committee.
Haydn Bechthold is a Law Student conducting his studies in Toronto. In 2021, at the young age of 22, Haydn received a stage 3C rectal cancer diagnosis, followed by the identification of Lynch syndrome. Because of his unique cancer journey, he has taken the admirable initiative to volunteer as a Patient Representative, supporting the Gastrointestinal Disease Site Committee at CCTG.
CCTG is happy to welcome Carol Hill who will be supporting the IND program as a Patient Representative.
Over the last six months, Centre Representatives and Contact CRAs at Canadian CCTG participating centres have been asked to share some of the challenges they’ve been experiencing around patient accrual and trial activations. This has included a Virtual Road Show of six 90-minute regional sessions and two surveys to supplement Road Show discussions and attempt to drill down on specific issues impacting accrual and trial activations, including around funding that may be impacting centres’ ability and capacity to activate and enroll patients to trials.
The Canadian Cancer Trials Group (CCTG) has now activated the symptom control trial SC29 evaluating high precision stereotactic body radiotherapy (SBRT) to conventional palliative radiotherapy (CRT) for patients with advanced cancer and a painful non-spine bone metastasis. SBRT represents a high dose treatment typically offered in the curative cancer setting; however, its role as a palliative treatment to improve pain for these patients is unknown.